嵌合抗原受體T細胞（CAR-T）治療的發展與護理

Development of Chimeric Antigen Receptor T Cells (CAR-T) Therapy and Its Nursing Care

10.6320/FJM.202105_25(3).0014

蘇啓軒(Chi-Hsuan Su)；李姵萱(Pei-Hsuan Lee)；許玉娟(Yu-Juan Xu)；姚明(Ming Yao)；陳佳慧(Cheryl Chia-Hui Chen)

癌症免疫治療 ； 嵌合抗原受體T細胞 ； 護理考量 ； cancer immunotherapy ； CAR-T ； nursing consideration

台灣醫學

25卷3期（2021 / 05 / 25）

411 - 416

繁體中文

免疫療法是癌症治療的趨勢，其中2017年於美國上市的CAR-T（chimeric antigen receptor T cells）治療是針對難治與復發型B細胞急性淋巴型白血病及非霍奇金式淋巴瘤的新興免疫治療方式。CAR-T治療利用病患本身T細胞作為載體，嵌合癌細胞抗原受體，以增強T細胞辨識癌細胞之能力，但也因其免疫功能增強，易造成包括細胞激素釋放症候群（cytokine release syndrome）與神經毒性（neurological toxicity）等主要副作用，病患在輸注CAR-T後會出現發燒、低血壓、低血氧、精神狀態改變與癲癇等現象；護理人員對於副作用徵象的及早辨別與護理將有助於降低副作用發生。本文概述CAR-T的治療、副作用及探討護理人員的角色，以期能強化護理人員在照護CAR-T治療之症狀識別與照護，提升護理照護品質與病人安全。

Cancer immunotherapy enhancing immune responses to fight cancer cells. As one kind of immunitherapies, chimeric antigen receptor T cells (CAR-T) therapy was launched in America at the year 2017 and had been indicated to treat refractory and relapse B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The CAR-T therapy involves modifing T cells to recognize cancer cells more effectively. Scientists harvest T cells (derived from T cells in a patient's own blood), genetically alter them, then infuse the resulting CAR-T cells into patients to attack their own cancer cells. With enhacing immune responses, cytokine release syndrome and neurological toxicity commonly occurred as adverse events. Patients may presented with fever, hypotension, hypoxemia, confusional state change with seizure episodes. In this article, we briefly introduce the CAR-T therapy and its adverse events with an eye toward promting the role of nurses in caring for these hightly voulnerable patients before, during, and after CAR-T therapy.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(Suppl 6):394-424.
   連結：
2. Taylor L, Rodriguez ES, Reese A, et al. Building a program: implications for infrastructure, nursing education, and training for CAR T-cell therapy. Clin J Oncol Nurs 2019;23(Suppl 2):20-6.
   連結：
3. Lamprecht M, Dansereau C. CAR T-cell therapy: update on the state of the science. Clin J Oncol Nurs 2019;23(Suppl 2): 6-12.
   連結：
4. Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 2018;19(Suppl 1):5-18.
   連結：
5. Callahan C, Baniewicz D, Ely B. CAR T-cell therapy: pediatric patients with relapsed and refractory acute lymphoblastic leukemia. Clin J Oncol Nurs 2017;21(Suppl 2):22-8.
   連結：
6. Buechner J, Kersten MJ, Fuchs M, et al. Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe. HemaSphere 2018;2(Suppl 1):e18.
   連結：
7. Anderson K, Latchford T. Associated toxicities: assessment and management related to CAR T-cell therapy. Clin J Oncol Nurs 2019;23(Suppl 2):13-9.
   連結：
8. Smith L, Venella K. Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy. Clin J Oncol Nurs 2017;21(Suppl 2):29-34.
   連結：
9. Shimabukuro-Vornhagen A, Godel P, Subklewe M, et al: Cytokine release syndrome. J Immunother Cancer 2018;6(Suppl 1):56.
   連結：
10. Baer B, Dudley CV, Simons RM. Management principles associated with cytokine release syndrome. Semin Oncol Nurs 2019;35(Suppl 5):150931.
    連結：
11. Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain 2019;142(Suppl 5):1334-48.
    連結：
12. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47-62.
    連結：
13. Neelapu SS. Managing the toxicities of car T‐cell therapy. Hematol Oncol 2019;37:48-52.
    連結：
14. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018;24(Suppl 6):739-48.
    連結：
15. Silbert S, Yanik GA, Shuman AG. How should we determine the value of CAR T-cell therapy? AMA J Ethics 2019;21(Suppl 10):E844-51.
    連結：
16. 衛生福利部：108年國人死因統計結果。https://www.mohw.gov.tw/cp-16-48057-1.html/ Accessed April 7, 2021.
17. Dougan M, Dranoff G. Immunotherapy of cancer. In Wang RF, ed. Innate immune regulation and cancer immunotherapy. New York, Springer, 2012:391-414.
18. The University of Texas MD Anderson Cancer Center: Chimeric antigen receptor (CAR) cell therapy toxicity assessment and management – Adult. https://www.mdanderson.org/documents/ for-physicians/algorithms/clinical-management/ clin-management-cytokine-release-web-algorithm.pdf/Accessed November 1, 2020.